These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 15929769)

  • 1. Will a 5-ASA a day keep the cancer (and dysplasia) away?
    Rubin DT; Lashner BA
    Am J Gastroenterol; 2005 Jun; 100(6):1354-6. PubMed ID: 15929769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Colorectal cancer in inflammatory bowel disease].
    Henriksen M; Moum B
    Tidsskr Nor Laegeforen; 2007 Oct; 127(20):2696-9. PubMed ID: 17952155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progression to colorectal neoplasia in ulcerative colitis: effect of mesalamine.
    Ullman T; Croog V; Harpaz N; Hossain S; Kornbluth A; Bodian C; Itzkowitz S
    Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1225-30; quiz 1177. PubMed ID: 18848502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: can we afford to wait for 'best evidence'?
    Giannini EG; Kane SV; Testa R; Savarino V
    Dig Liver Dis; 2005 Oct; 37(10):723-31. PubMed ID: 16023905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoprevention for colon cancer: new opportunities, fact or fiction?
    Terhaar Sive Droste JS; Tuynman JB; Van Dullemen HM; Mulder CJ
    Scand J Gastroenterol Suppl; 2006; (243):158-64. PubMed ID: 16782636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of chemoprevention of colorectal cancer with 5-aminosalicylates in ulcerative colitis.
    Herfarth H
    Dig Dis; 2012; 30 Suppl 2():55-9. PubMed ID: 23207933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Does 5-ASA prevent development of colon cancer in ulcerative colitis?].
    Fallingborg JF
    Ugeskr Laeger; 2006 May; 168(21):2049-51. PubMed ID: 16768921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-aminosalicylic acid given in the remission stage of colitis suppresses colitis-associated cancer in a mouse colitis model.
    Ikeda I; Tomimoto A; Wada K; Fujisawa T; Fujita K; Yonemitsu K; Nozaki Y; Endo H; Takahashi H; Yoneda M; Inamori M; Kubota K; Saito S; Nagashima Y; Nakagama H; Nakajima A
    Clin Cancer Res; 2007 Nov; 13(21):6527-31. PubMed ID: 17975166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial.
    Hanai H; Iida T; Takeuchi K; Watanabe F; Maruyama Y; Andoh A; Tsujikawa T; Fujiyama Y; Mitsuyama K; Sata M; Yamada M; Iwaoka Y; Kanke K; Hiraishi H; Hirayama K; Arai H; Yoshii S; Uchijima M; Nagata T; Koide Y
    Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1502-6. PubMed ID: 17101300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease.
    Chan EP; Lichtenstein GR
    Gastroenterol Clin North Am; 2006 Sep; 35(3):675-712. PubMed ID: 16952746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesalamine restores angiogenic balance in experimental ulcerative colitis by reducing expression of endostatin and angiostatin: novel molecular mechanism for therapeutic action of mesalamine.
    Deng X; Tolstanova G; Khomenko T; Chen L; Tarnawski A; Szabo S; Sandor Z
    J Pharmacol Exp Ther; 2009 Dec; 331(3):1071-8. PubMed ID: 19762547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of colorectal cancer in inflammatory bowel disease: value of screening and 5-aminosalicylates.
    Munkholm P; Loftus EV; Reinacher-Schick A; Kornbluth A; Mittmann U; Esendal B
    Digestion; 2006; 73(1):11-9. PubMed ID: 16410688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacological profile and clinical use of mesalazine (5-aminosalicylic acid).
    Klotz U
    Arzneimittelforschung; 2012 Feb; 62(2):53-8. PubMed ID: 22344548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoprevention of colorectal cancer: feasibility in everyday practice?
    Herszényi L; Farinati F; Miheller P; Tulassay Z
    Eur J Cancer Prev; 2008 Nov; 17(6):502-14. PubMed ID: 18941372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [5-aminosalicylic acid and cancer prophylaxis?].
    Thomsen OO
    Ugeskr Laeger; 2006 May; 168(21):2047. PubMed ID: 16768920
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis.
    Bajpai M; Seril DN; Van Gurp J; Geng X; Alvarez J; Minacapelli CD; Gorin S; Das KK; Poplin E; Cheng J; Amenta PS; Das KM
    Dig Dis Sci; 2019 Mar; 64(3):740-750. PubMed ID: 30478770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Encapsulated mesalamine granules (Apriso) for ulcerative colitis.
    Med Lett Drugs Ther; 2009 May; 51(1312):38-9. PubMed ID: 19448588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis.
    Rubin DT; LoSavio A; Yadron N; Huo D; Hanauer SB
    Clin Gastroenterol Hepatol; 2006 Nov; 4(11):1346-50. PubMed ID: 17059900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis.
    Qiu X; Ma J; Wang K; Zhang H
    Oncotarget; 2017 Jan; 8(1):1031-1045. PubMed ID: 27906680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Inflammatory bowel disease and colorectal cancer].
    Hagymási K; Tulassay Z
    Orv Hetil; 2006 Oct; 147(41):1977-82. PubMed ID: 17120688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.